The landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their uptake remains cautious. The government navigates the fine line between accessibility and safety, implementing regulations that restrict direct marketing and monitor potential abuse.

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moderating. Doctors note that physician…

The landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their uptake remains cautious. The government…

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns about misuse for cosmetic reasons are…